Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Tiotropium bromide

Study type: Observational

Funder types: Industry

Identifiers

NCT02172482

205.277

Details and patient eligibility

About

As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice

Enrollment: 63,127 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women aged at least 40 years presenting with the symptoms of COPD

Exclusion criteria

• Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information

Trial design

63,127 participants in 1 patient group

Symptoms of COPD

Description:

Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms

Treatment:

Drug: Tiotropium bromide